{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:47:28Z","timestamp":1785523648285,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,13]],"date-time":"2027-05-13T00:00:00Z","timestamp":1810166400000},"content-version":"am","delay-in-days":619,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H05473"],"award-info":[{"award-number":["23H05473"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117721","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T13:39:41Z","timestamp":1746970781000},"page":"117721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5059-3244","authenticated-orcid":false,"given":"Yosuke","family":"Nishigaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunobu","family":"Sumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Kikuzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hiroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Maemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Namie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Shirouzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117721_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nbt.1685","article-title":"Epigenetic modifications and human disease","volume":"28","author":"Portela","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.117721_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1039\/C0MD00062K","article-title":"Targeting epigenetic modifiers: inhibitors of histone methyltransferases","volume":"1","author":"Bissinger","year":"2010","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2025.117721_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbagrm.2008.06.005","article-title":"Chemical mechanisms of histone lysine and arginine modifications","volume":"1789","author":"Smith","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2025.117721_bib4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117721_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/cb500785t","article-title":"Chemical probes of histone lysine methyltransferases","volume":"10","author":"Kaniskan","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117721_bib6","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/jm501234a","article-title":"Selective inhibitors of protein methyltransferases","volume":"58","author":"Kaniskan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117721_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2025.117721_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117721_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.genet.032608.103928","article-title":"Histones: annotating chromatin","volume":"43","author":"Campos","year":"2009","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ejmech.2025.117721_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg2005","article-title":"Cancer epigenomics: DNA methylomes and histone-modification maps","volume":"8","author":"Esteller","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejmech.2025.117721_bib11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117721_bib12","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/nn.4165","article-title":"G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition","volume":"18","author":"Laumet","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117721_bib13","doi-asserted-by":"crossref","first-page":"127111","DOI":"10.1172\/jci.insight.127111","article-title":"CBX5\/G9a\/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis","volume":"5","author":"Ligresti","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2025.117721_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ki.2015.291","article-title":"Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression","volume":"89","author":"Irifuku","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2025.117721_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jir.2015.0006","article-title":"Inhibition of EHMT2 induces a robust antiviral response against foot-and-mouth disease and vesicular stomatitis virus infections in bovine cells","volume":"36","author":"Singh","year":"2016","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejmech.2025.117721_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep34163","article-title":"G9a inhibits MEF2C activity to control sarcomere assembly","volume":"6","author":"Ow","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117721_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4257","article-title":"Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome","volume":"23","author":"Kim","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117721_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejmech.2019.06.072","article-title":"Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents","volume":"179","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117721_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood-2015-02-629972","article-title":"Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR\/\u03b3-globin looping","volume":"126","author":"Krivega","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117721_bib20","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","article-title":"Reawakening fetal hemoglobin: prospects for new therapies for the \u03b2-globin disorders","volume":"120","author":"Bauer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117721_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117721_bib22","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1021\/acs.jmedchem.7b01926","article-title":"Discovery of reversible DNA methyltransferase and lysine methyltransferase G9a inhibitors with antitumoral in vivo efficacy","volume":"61","author":"Rabal","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117721_bib23","doi-asserted-by":"crossref","first-page":"15424","DOI":"10.1038\/ncomms15424","article-title":"Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies","volume":"8","author":"San Jos\u00e9-En\u00e9riz","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117721_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/ml400496h","article-title":"Discovery and development of potent and selective inhibitors of histone methyltransferase g9a","volume":"5","author":"Sweis","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131716","article-title":"The histone methyltransferase inhibitor A-366 uncovers a role for G9a\/GLP in the epigenetics of leukemia","volume":"10","author":"Pappano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117721_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127475","article-title":"Discovery of novel histone lysine methyltransferase G9a\/GLP (EHMT2\/1) inhibitors: design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines","volume":"30","author":"Katayama","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/acsmedchemlett.0c00572","article-title":"Discovery of DS79932728: a potent, orally available G9a\/GLP inhibitor for treating \u03b2-Thalassemia and sickle cell disease","volume":"12","author":"Katayama","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib28","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.ymthe.2024.05.034","article-title":"Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.117721_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41467-022-35404-0","article-title":"A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression","volume":"14","author":"Takase","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117721_bib30","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jmedchem.2c02059","article-title":"Discovery of novel substrate-competitive lysine methyltransferase G9a inhibitors as anticancer agents","volume":"66","author":"Nishigaya","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117721_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129856","article-title":"Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment","volume":"110","author":"Nishigaya","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib32","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1073\/pnas.1605523113","article-title":"S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3","volume":"113","author":"Jayaram","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117721_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059890","article-title":"Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells","volume":"8","author":"Kurita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117721_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0009-2614(99)00874-X","article-title":"Fragment molecular orbital method: an approximate computational method for large molecules","volume":"313","author":"Kitaura","year":"1999","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib35","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1039\/C4CP00316K","article-title":"Electron-correlated fragment-molecular-orbital calculations for biomolecular and nano systems","volume":"16","author":"Tanaka","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.117721_bib36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0009-2614(00)00070-1","article-title":"Fragment molecular orbital method: application to polypeptides","volume":"318","author":"Nakano","year":"2000","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0009-2614(01)01416-6","article-title":"Fragment molecular orbital method: use of approximate electrostatic potential","volume":"351","author":"Nakano","year":"2002","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cplett.2011.12.004","article-title":"Development of the four-body corrected fragment molecular orbital (FMO4) method","volume":"523","author":"Nakano","year":"2012","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.ejmech.2025.117721_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.csbj.2018.10.003","article-title":"Towards good correlation between fragment molecular orbital interaction energies and experimental IC50 for ligand binding: a case study of p38 MAP kinase","volume":"16","author":"Sheng","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2025.117721_bib40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/cbic.200400005","article-title":"Structure-based design, synthesis, and in vitro evaluation of nonpeptidic neprilysin inhibitors","volume":"5","author":"Sahli","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.117721_bib41","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","article-title":"Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription","volume":"59","author":"Takemoto","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117721_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112388","article-title":"Lysine long-chain fatty acylation regulates the TEAD transcription factor","volume":"42","author":"Noritsugu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117721_bib43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.2005.05646.x","article-title":"Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry","volume":"130","author":"Daniel","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.117721_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2025.117721_bib45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.117721_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2025.117721_bib47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2025.117721_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2025.117721_bib49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2025.117721_bib50","unstructured":"Maestro Schr\u00f6dinger Inc., New York, NY, USA, http:\/\/www.schrodinger.com\/."},{"key":"10.1016\/j.ejmech.2025.117721_bib52","series-title":"MIZUHO\/BioStation Viewer, Version 3.0; Mizuho Information and Research Institute: Tokyo","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117721_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1273\/cbij.19.5","volume":"19","author":"Watanabe","year":"2019","journal-title":"CBIJ"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:06:36Z","timestamp":1762265196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"alternative-id":["S0223523425004866"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117721","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent substrate-type lysine methyltransferase G9a inhibitors for the treatment of sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117721"}}